MANNKIND CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MANNKIND CORP (MNKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $4.70M, a 34.29% increase from fiscal 2024.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.50M, a 169.23% increase from fiscal 2023.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.30M, a 45.83% decline from fiscal 2022.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.40M, a 41.18% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $4.70M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.50M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.30M 10-K · filed 2026-02-26 |
| 2022-12-31 | $2.40M 10-K · filed 2025-02-26 |
| 2021-12-31 | $1.70M 10-K · filed 2024-02-27 |
| 2020-12-31 | $500.00K 10-K · filed 2023-02-23 |
| 2016-12-31 | $100.00K 10-K · filed 2019-02-26 |
| 2015-12-31 | $6.20M 10-K · filed 2018-02-27 |
| 2014-12-31 | $14.90M 10-K · filed 2017-03-16 |
| 2013-12-31 | $3.10M 10-K · filed 2016-03-15 |
| 2012-12-31 | $1.00K 10-K · filed 2015-03-02 |
| 2011-12-31 | $443.00K 10-K · filed 2014-03-03 |
| 2010-12-31 | $1.60M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |